Red Ginseng for Health & Longevity - Quick Reference Sheet

Red Ginseng for Health & Longevity

Created on 08/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

The steamed root of an East Asian plant. Its most repeatable effects show up in blood tests, not in how people feel: lower fasting blood sugar, better insulin sensitivity, lower inflammation markers where inflammation is already raised. Effects on tiredness, erectile function, and memory are small. Sleep disruption, digestive upset, drug interactions, and variable product potency are the concerns. (Full Review)

Protocol

Standard dose
2–3 g/day
Korean red ginseng root powder or an equivalent standardized extract. Most positive trials used 1–3 g/day.
Split dosing
Two or three doses with meals
Splitting reduces the gastrointestinal irritation seen with single large doses.
Time of day
Morning and midday
The last dose falls well before 16:00; evening dosing is the most common cause of insomnia.
Time to effect
Glucose and inflammatory markers
8–12 weeks
The shortest interval at which trials detected change.
Antioxidant enzyme changes
More than 4 weeks
Senescence marker changes run on the same timescale.
Subjective energy changes
2–4 weeks
When they occur.

Benefits

Contraindications
  • Pregnancy (particularly the first trimester) and lactation
  • Hormone-sensitive cancers (estrogen-receptor-positive breast cancer, endometrial cancer, uterine fibroids under active management)
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline)
  • Uncontrolled hypertension (resting systolic above 160 mmHg or diastolic above 100 mmHg) until controlled
  • Personal or family history of mania or bipolar disorder
  • Within 7 days of scheduled surgery, or platelet count below 100,000 per microlitre
Key Interactions
  • Warfarin
  • Insulin, sulfonylureas, and metformin
  • Antihypertensives (amlodipine, lisinopril, losartan)
  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, apixaban)
  • P-glycoprotein substrates (digoxin, dabigatran, fexofenadine)
  • Immunosuppressants (tacrolimus, ciclosporin, mycophenolate)
  • Caffeine and other stimulants
  • Alcohol
  • Other blood-sugar-lowering supplements (berberine, chromium, cinnamon extract, alpha-lipoic acid)
  • Other blood-pressure-lowering supplements (beetroot nitrate, magnesium, garlic extract, potassium)

Risk & Side Effects

  • High: Insomnia and overstimulation; headache; gastrointestinal upset
  • Medium: Additive blood-sugar lowering with diabetes medication; altered anticoagulation with warfarin; estrogen-receptor activation
  • Low: Raised serum bilirubin at higher doses; raised blood pressure at high doses; serious events from adulterated combination products
  • Speculative: Teratogenic potential in pregnancy; agitation with monoamine oxidase inhibitors; cardiac rhythm disturbance

Monitoring

Marker Target Why
Fasting Glucose 75–85 mg/dL Primary efficacy target; largest and most replicated effect
Hemoglobin A1c 4.8–5.3% Confirms that any glucose change is sustained, not transient
Fasting Insulin 2–5 μIU/mL Detects insulin sensitivity gains that glucose alone misses
High-Sensitivity C-Reactive Protein Below 0.8 mg/L Anti-inflammatory benefit occurs almost only above 3 mg/L
Seated Blood Pressure 110–120 / 70–78 mmHg Captures both the small expected fall and the high-dose elevation signal
Alanine Aminotransferase 10–26 U/L (women), 10–30 U/L (men) Screens for liver injury, which pooled data do not support but which cannot be assumed
Total Bilirubin 0.3–1.0 mg/dL The one liver marker that did shift, specifically at ≥3 g/day
International Normalized Ratio No universal target — track against the individual's own pre-ginseng value and prescribed range Detects the disputed warfarin interaction before bleeding or clotting occurs

Cadence: Baseline panel before starting. Blood pressure weekly for the first 2 weeks; clotting time at 2 and 4 weeks in warfarin users and again after stopping. Full metabolic and inflammatory panel at 12 weeks, then every 6–12 months on continued use.

Qualitative Assessment

  • Sleep latency and number of night awakenings, recorded for the first 2 weeks
  • Daytime energy and afternoon fatigue, rated 0–10 each evening
  • Memory and word-finding in ordinary conversation
  • Perceived exertion during a familiar training session at a fixed load
  • Digestive comfort in the hours following each dose
  • Frequency and duration of upper respiratory infections across a full winter